Vax ImmuneThe Center for Innovation Partner on Proprietary Device
(MENAFNEditorial) Vax-Immune and The Consortium for Technology and Innovation in Pediatrics a Device Accelerator Run by Childrens Hospital Los Angeles Partner in the Development of Vax-Immunes Proprietary Device
Vax-Immune LLC is pleased to announce its partnership with The Consortium for Technology and Innovation in Pediatrics (CTIP) in developing Vax-Immunes platform device to aid in the rapid diagnosis of infection. CTIP a pediatric medical device accelerator funded by the U.S. food and Drug Administration and operated by Childrens Hospital Los Angeles will provide product development and commercialization assistance to Vax-Immune.
Vax-Immune has developed a proprietary hand-held portable and disposable culture device as its first product which is poised to dramatically improve the diagnosis and treatment of infection in pregnant women and babies. Infections by Group B Streptococcus (GBS) Ureaplasma (UP) and E. Coli (EC) transmitted to the baby during delivery are the primary cause of neonatal morbidity and mortality in the developed world and the primary cause of prolonged hospital stay for the mom. By quickly and accurately identifying infections doctors can initiate the correct treatment immediately thus avoiding a lengthy and expensive diagnostic process and preventing undue suffering from these conditions. The potential annual saving in hospital stays for infected moms and babies treated for infection is estimated to be over $15 billion in the United States alone.
Rapid diagnosis of GBS Ureaplasma E. Coli and other infections will quickly provide the obstetrician pediatrician family practitioner and neonatologist answers they need reducing misdiagnosis and delay in treatment that can lead to pain suffering chronic and fatal conditions.
Leonard E. Weisman MD President and Chief Technology Officer of Vax-Immune stated Our Company and our products are dedicated to improving patient care. With the discoveries we have made we are positioned to significantly change the way infections are diagnosed and treated in pregnancy and in the neonatal intensive care units at hospitals around the world. We are poised to improve the health of pregnant moms and babies and create opportunities for hospitals and insurance companies to save millions.
We are happy to count Vax-Immune among our portfolio of CTIP-supported companies said Jessica Rousset director Center for Innovation at CHLA and CTIP co-director. Vax-Immune seeks to better manage infections that affect 60000 babies each year in the U.S. alone. Current standard of care dictates broad spectrum antibiotic use which may not be effective against the causative pathogen.
ABOUT VAX-IMMUNE LLC
Vax-Immune based in Houston Texas is led by a team of physicians research scientists business and financial leaders marketing professionals and entrepreneurs experienced in medical product development and commercialization. Vax-Immune has patents and patents pending for their innovative solutions to rapidly diagnose treat and prevent infection. For more information they can be contacted at infovaximmune.com or you can learn about Vax-Immune at http://www.vaximmune.com.
ABOUT THE CONSORTIUM FOR TECHNOLOGY AND INNOVATION
The Consortium for Technology and Innovation (CTIP) is an FDA-funded consortium accelerating novel pediatric medical device development. CTIP which is operated by Childrens Hospital Los Angeles provides a broad range of resources to leading academic institutions healthcare providers entrepreneurs and corporations to advance pediatric medical device commercialization. For more information about CTIP email: innovationchla.usc.edu or learn more at http://www.scctip.com
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.